Understanding the Challenges of Better Health
In The Dr. Berg Show LIVE - September 25, 2026, we delve into vital discussions on health, leading us to further explore the significant aspects of wellness for everyone.
Related Posts All Posts
09.26.2026
Discovering Phelan-McDermid Syndrome: A Condition More Common Than Believed
Update Understanding Phelan-McDermid Syndrome: A Hidden Challenge A recent study led by the Seaver Autism Center for Research and Treatment at Mount Sinai has uncovered startling findings about Phelan-McDermid syndrome (PMS), a genetic disorder closely associated with autism. Previously considered rare, new estimates indicate that PMS may actually affect approximately 1 in 7,300 individuals, suggesting that over 45,000 Americans could be living with this condition, many undiagnosed. This revelation could prompt a re-evaluation of how we approach autism diagnosis and support. Why Are So Many Cases Undiagnosed? The large gap between known diagnoses and the estimated prevalence of PMS is primarily attributed to the lack of genetic testing offered to patients with autism. "Many individuals with developmental disabilities are never provided the opportunity for genetic screening," notes Tess Levy, MSc, one of the key researchers of the study. The barrier to diagnosis is further complicated by insufficient insurance coverage and the inadequacy of tests that don’t comprehensively assess the SHANK3 gene. As many families are not aware that genetic testing is an option, many individuals remain without a diagnosis, missing the critical support they may need. The Implications of Genetic Testing Genetic testing is critical not only for diagnosing conditions like PMS but also for informing future treatments. Joseph D. Buxbaum, PhD, emphasizes that understanding genetic profiles "allows researchers to develop more targeted clinical trials for potential therapies." Since PMS is linked to autism spectrum disorder—affecting roughly one percent of autism cases—early diagnosis could pave the way for tailored interventions that cater to an individual's specific needs. This tailored approach can lead to better management of symptoms, ultimately improving quality of life for those affected. Broader Access to Genetic Testing Advocates for wider genetic testing urge that all children diagnosed with autism should be tested. This step could empower families with knowledge that helps them navigate their child's developmental challenges more effectively. In many instances, families may struggle to understand their child’s behavior or developmental delays without a clear diagnosis. With new treatments entering clinical trials, there is hope that the coming years will bring significant advancements in the management of PMS, offering families new avenues for support and intervention. Looking Ahead: Future Prognosis for Phelan-McDermid Syndrome As research on PMS progresses, the potential for effective treatments grows. The collaboration between CureSHANK and Neuren Pharmaceuticals represents not only a significant research effort but also a beacon of hope for families grappling with this condition. Dr. Buxbaum predicts that within five years, significant strides will be made in developing impactful therapies resulting from these genetic discoveries. This timeline offers a sense of optimism to parents and caregivers who are currently seeking solutions for their loved ones. Raising Awareness and Understanding Moreover, raising public awareness about Phelan-McDermid syndrome is crucial. By sharing stories and experiences of those impacted, we can foster a more inclusive community that recognizes the diverse challenges facing families. Communities must understand that every diagnosis is unique, and individuals with PMS may exhibit a range of symptoms that are often misunderstood or misattributed. With the proper dialogue, the stigma surrounding genetic disorders can be diminished, encouraging more families to seek the help they need and fostering an environment of support and understanding. Conclusion: Knowledge is Power The compelling evidence brought to light by this recent research reiterates the importance of genetic testing in uncovering and managing conditions like Phelan-McDermid syndrome. Early diagnosis can lead to better outcomes, and with advocacy, public awareness can lead to action. Genetic disorders affect not only those diagnosed but their families and communities as well. Enhanced testing has the potential to shift the narrative surrounding autism and developmental disabilities, promising support and better healthcare pathways for those impacted. It is essential for parents, educators, and healthcare providers to work together to ensure that genetic testing becomes a standard component of autism evaluations. This proactive approach can illuminate the path forward for countless families who may otherwise remain in the dark.
09.26.2026
New CRISPR Technique Attacks Blood Cancer With Minimal Harm to Healthy Cells
Update CRISPR: A New Hope for Blood Cancer TreatmentIn a groundbreaking advancement for the treatment of aggressive blood cancers, researchers at Washington University School of Medicine in St. Louis have utilized CRISPR gene editing technology to enhance the effectiveness of stem cell transplants. This innovative method allows doctors to target cancer cells more precisely without harming the healthy blood cells crucial for patient recovery. With promising results from a recent clinical trial, this strategy could revolutionize how we combat diseases like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), which have long been challenging to treat.Understanding the Challenge of Traditional TreatmentsCurrently, treatments such as CAR-T cell therapy have shown great promise, particularly for certain aggressive blood cancers. However, their effectiveness is often diminished by a significant drawback: the overlapping presence of certain proteins on both healthy and cancerous cells. This overlap can lead to CAR-T cells attacking healthy blood stem cells alongside cancer cells, potentially triggering severe side effects such as life-threatening inflammation. The new CRISPR approach aims to resolve this issue, providing a safer and more effective route for treatment.The Power of Gene EditingThe highlights of the study, published in Nature Medicine, reveal that the researchers successfully modified donor stem cells to remove the CD33 protein, which is found in high levels on many AML and MDS cells. Dr. John F. DiPersio, a lead investigator of the trial, has noted that the results were encouraging, with modified stem cells sustaining healthy blood cell outcomes comparable to those of traditional stem cell transplants. The approach not only minimizes the risk of damaging healthy cells but also enhances the overall safety of subsequent therapies.Real-World Impact: A Patient's JourneyOne stark example demonstrating this technology's potential involves a patient who underwent a CD33-deleted stem cell transplant. After experiencing a return of their cancer, that very patient was subsequently treated using CD33-targeted CAR-T cells derived from the same donor. This case illustrates the future implications of tailored therapies working collaboratively to improve patient outcomes. By combining innovative stem cell transplants with targeted CAR-T treatments, there is a hopeful possibility of developing personalized treatment strategies that could extend survival for those suffering from aggressive blood cancers.Collaborative Research EffortsThe clinical trial was performed at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, alongside 14 other sites across the U.S. and Canada. This extensive collaboration emphasizes the importance of sharing knowledge and resources in advancing cancer research. As ongoing trials continue to refine and test these therapies, maintaining such cooperative efforts is crucial for broadening understandings of their effectiveness.A Bright Future in Cancer TherapyThe implications of this research extend beyond mere treatment possibilities; they represent hope for numerous patients facing dire prognoses in the battle against blood cancers. As researchers conduct more studies to confirm their findings, this CRISPR-based approach stands not only to change the paradigm of cancer treatment but also to allow for less toxic therapies. These advancements could spare patients from the harmful side effects often associated with conventional cancer treatments, making the fight against blood cancers more humane.Conclusion: Why It MattersThe advancements made by researchers in St. Louis reflect a broader movement in medicine towards more targeted and personalized interventions. For patients navigating the complexities of aggressive blood cancers, this research signifies a vital step forward in oncology. As we await further trials and the eventual integration of these findings into clinical practice, there is renewed optimism that tackling blood cancers could become increasingly effective, precise, and humane. In this evolving landscape of cancer treatment, CRISPR is at the forefront of the quest to save lives, potentially transforming the outlook for those diagnosed with once-terminal conditions.
09.25.2026
Revolutionary Discovery in Cellular Survival Pathway May Transform Cancer Treatment
Update An Unexpected Cellular Discovery In a groundbreaking revelation, researchers at Montana State University have unveiled an astonishing cellular survival pathway that could revolutionize our understanding of how mammalian cells, including cancer cells, manage to synthesize the essential amino acid cysteine. Under normal circumstances, cells are thought to rely on a disulfide reductase system to convert cystine, a more oxidized form of cysteine, into usable cysteine. This process was once deemed non-negotiable for cellular life. The Role of Cysteine in Cell Survival Cysteine is a vital amino acid that plays multiple roles in cellular function. Not only is it necessary for protein synthesis, but it also serves as a protective agent against potential cellular damage. Additionally, cysteine is crucial for forming disulfide bonds that help stabilize proteins. These bonds are integral for maintaining the three-dimensional structures of proteins, ensuring their proper function. Challenging Long-Standing Assumptions For decades, scientists believed that the absence of at least one functioning disulfide reductase meant certain death for mammalian cells. However, the recent findings by Ed Schmidt and his team have shattered this long-held belief. It started with peculiar observations from genetically engineered mice, which survived in conditions that were previously thought to be lethal. Schmidt noted, “This was supposed to be impossible. No living organism or cell had ever been found that could live without a functioning disulfide reductase system.” Yet, these mice thrived in the face of adversity. A Hidden Backup System Through meticulous experimentation over nine years, Schmidt's team, in collaboration with partners from the Hungarian National Institute of Oncology, discovered that mammalian cells possess a previously unknown chemical route for synthesizing cysteine. This alternative pathway allows cells to generate cysteine, even when the standard systems fail. These extraordinary findings, published in the journal Nature Chemical Biology, may have significant implications for cancer treatment. Implications for Cancer Treatment Understanding this backup mechanism could lead to novel strategies for targeting cancer cells. Tumors often exploit such survival pathways to resist treatments, making them more difficult to eliminate. If researchers can devise methods to inhibit this newly discovered route, it may enhance the efficacy of existing cancer therapies, rendering resistant tumors more susceptible to treatments. Indeed, Schmidt's work opens the door to new questions about the adaptability of cancer cells and their survival strategies. The Path Forward: Research and Innovation This discovery highlights the importance of continuously challenging scientific norms and exploring the unknown. As scientists further investigate this alternative cysteine synthesis route, there lies potential for innovative approaches to combat difficult-to-treat cancers. The ongoing research also represents a pivotal moment in genetic and cellular biology, signifying how advancing knowledge can lead to breakthroughs that reshape medical practices. Conclusion As this research progresses, the scientific community remains hopeful that novel therapies can emerge from these findings. By unraveling the mysteries of cellular survival, particularly in cancer cells, we grasp closer to unlocking new treatments that could transform patient outcomes in the future. Scientists and medical professionals alike are encouraged to stay tuned to this promising line of inquiry, which may ultimately lead to enhanced strategies in the fight against cancer.
Keeping you well-informed and well-connected to Big D.
This is a custom HTML / JavaScript Element
In order To See Your Custom HTML/JavaScript Code in Action You Must Click On The Preview Page Button, Your Code is NOT going to be active in the edit mode
{"js":"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","embed":""}
© 2026 Dallas Living All Rights Reserved. ,, Dallas, TX 75001 . Contact Us . Terms of Service . Privacy Policy
{"company":"Dallas Living","address":",","city":"Dallas","state":"TX","zip":"75001","email":"sanantonioliving78205@gmail.com","tos":"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","privacy":"PHA+PHN0cm9uZz5QUklWQUNZPC9zdHJvbmc+PC9wPgoKPHA+PHN0cm9uZz5UaGUgaW5mb3JtYXRpb24gcHJvdmlkZWQgZHVyaW5nIHRoaXMgcmVnaXN0cmF0aW9uIGlzIGtlcHQgcHJpdmF0ZSBhbmQgY29uZmlkZW50aWFsLCBhbmQgd2lsbCBuZXZlciBiZSBkaXN0cmlidXRlZCwgY29waWVkLCBzb2xkLCB0cmFkZWQgb3IgcG9zdGVkIGluIGFueSB3YXksIHNoYXBlIG9yIGZvcm0uIFRoaXMgaXMgb3VyIGd1YXJhbnRlZS48L3N0cm9uZz48L3A+Cgo8cD48c3Ryb25nPklOREVNTklUWTwvc3Ryb25nPjwvcD4KCjxwPjxlbT5Zb3UgYWdyZWUgdG8gaW5kZW1uaWZ5IGFuZCBob2xkIHVzLCBhbmQgaXRzIHN1YnNpZGlhcmllcywgYWZmaWxpYXRlcywgb2ZmaWNlcnMsIGFnZW50cywgY28tYnJhbmRlcnMgb3Igb3RoZXIgcGFydG5lcnMsIGFuZCBlbXBsb3llZXMsIGhhcm1sZXNzIGZyb20gYW55IGNsYWltIG9yIGRlbWFuZCwgaW5jbHVkaW5nIHJlYXNvbmFibGUgYXR0b3JuZXlzJiMzOTsgZmVlcywgbWFkZSBieSBhbnkgdGhpcmQgcGFydHkgZHVlIHRvIG9yIGFyaXNpbmcgb3V0IG9mIENvbnRlbnQgeW91IHJlY2VpdmUsIHN1Ym1pdCwgcmVwbHksIHBvc3QsIHRyYW5zbWl0IG9yIG1ha2UgYXZhaWxhYmxlIHRocm91Z2ggdGhlIFNlcnZpY2UsIHlvdXIgdXNlIG9mIHRoZSBTZXJ2aWNlLCB5b3VyIGNvbm5lY3Rpb24gdG8gdGhlIFNlcnZpY2UsIHlvdXIgdmlvbGF0aW9uIG9mIHRoZSBUT1MsIG9yIHlvdXIgdmlvbGF0aW9uIG9mIGFueSByaWdodHMgb2YgYW5vdGhlci48L2VtPjwvcD4KCjxwPjxzdHJvbmc+RElTQ0xBSU1FUiBPRiBXQVJSQU5USUVTPC9zdHJvbmc+PC9wPgoKPHA+PHN0cm9uZz5ZT1UgRVhQUkVTU0xZIFVOREVSU1RBTkQgQU5EIEFHUkVFIFRIQVQ6PC9zdHJvbmc+PC9wPgoKPG9sPgoJPGxpPllPVVIgVVNFIE9GIFRIRSBTRVJWSUNFIElTIEFUIFlPVVIgU09MRSBSSVNLLiBUSEUgU0VSVklDRSBJUyBQUk9WSURFRCBPTiBBTiAmcXVvdDtBUyBJUyZxdW90OyBBTkQgJnF1b3Q7QVMgQVZBSUxBQkxFJnF1b3Q7IEJBU0lTLiAsLiBBTkQgVVMsIElUJiMzOTtTIENVU1RPTUVSUywgRVhQUkVTU0xZIERJU0NMQUlNUyBBTEwgV0FSUkFOVElFUyBPRiBBTlkgS0lORCwgV0hFVEhFUiBFWFBSRVNTIE9SIElNUExJRUQsIElOQ0xVRElORywgQlVUIE5PVCBMSU1JVEVEIFRPIFRIRSBJTVBMSUVEIFdBUlJBTlRJRVMgT0YgTUVSQ0hBTlRBQklMSVRZLCBGSVRORVNTIEZPUiBBIFBBUlRJQ1VMQVIgUFVSUE9TRSBBTkQgTk9OLUlORlJJTkdFTUVOVC48L2xpPgoJPGxpPk1BS0VTIE5PIFdBUlJBTlRZIFRIQVQgKGkpIFRIRSBTRVJWSUNFIFdJTEwgTUVFVCBZT1VSIFJFUVVJUkVNRU5UUywgKGlpKSBUSEUgU0VSVklDRSBXSUxMIEJFIFVOSU5URVJSVVBURUQsIFRJTUVMWSwgU0VDVVJFLCBPUiBFUlJPUi1GUkVFLCAoaWlpKSBUSEUgUkVTVUxUUyBUSEFUIE1BWSBCRSBPQlRBSU5FRCBGUk9NIFRIRSBVU0UgT0YgVEhFIFNFUlZJQ0UgV0lMTCBCRSBBQ0NVUkFURSBPUiBSRUxJQUJMRSwgQU5EIChpdikgQU5ZIEVSUk9SUyBJTiBUSEUgU09GVFdBUkUgV0lMTCBCRSBDT1JSRUNURUQuPC9saT4KCTxsaT5BTlkgTUFURVJJQUwgRE9XTkxPQURFRCBPUiBPVEhFUldJU0UgT0JUQUlORUQgVEhST1VHSCBUSEUgVVNFIE9GIFRIRSBTRVJWSUNFIElTIERPTkUgQVQgWU9VUiBPV04gRElTQ1JFVElPTiBBTkQgUklTSyBBTkQgVEhBVCBZT1UgV0lMTCBCRSBTT0xFTFkgUkVTUE9OU0lCTEUgRk9SIEFOWSBEQU1BR0UgVE8gWU9VUiBDT01QVVRFUiBTWVNURU0gT1IgTE9TUyBPRiBEQVRBIFRIQVQgUkVTVUxUUyBGUk9NIFRIRSBET1dOTE9BRCBPRiBBTlkgU1VDSCBNQVRFUklBTC48L2xpPgoJPGxpPk5PIEFEVklDRSBPUiBJTkZPUk1BVElPTiwgV0hFVEhFUiBPUkFMIE9SIFdSSVRURU4sIE9CVEFJTkVEIEJZIFlPVSBGUk9NIE9SIFRIUk9VR0ggT1IgRlJPTSBUSEUgU0VSVklDRSBTSEFMTCBDUkVBVEUgQU5ZIFdBUlJBTlRZIE5PVCBFWFBSRVNTTFkgU1RBVEVEIElOIFRIRSBUT1MuPC9saT4KPC9vbD4KCjxwPjxzdHJvbmc+TElNSVRBVElPTiBPRiBMSUFCSUxJVFk8L3N0cm9uZz48L3A+Cgo8cD5ZT1UgRVhQUkVTU0xZIFVOREVSU1RBTkQgQU5EIEFHUkVFIFRIQVQgQU5EIFNIQUxMIE5PVCBCRSBMSUFCTEUgRk9SIEFOWSBESVJFQ1QsIElORElSRUNULCBJTkNJREVOVEFMLCBTUEVDSUFMLCBDT05TRVFVRU5USUFMIE9SIEVYRU1QTEFSWSBEQU1BR0VTLCBJTkNMVURJTkcgQlVUIE5PVCBMSU1JVEVEIFRPLCBEQU1BR0VTIEZPUiBMT1NTIE9GIFBST0ZJVFMsIEdPT0RXSUxMLCBVU0UsIERBVEEgT1IgT1RIRVIgSU5UQU5HSUJMRSBMT1NTRVMgKEVWRU4gSUYgSEFTIEJFRU4gQURWSVNFRCBPRiBUSEUgUE9TU0lCSUxJVFkgT0YgU1VDSCBEQU1BR0VTKSwgUkVTVUxUSU5HIEZST006PC9wPgoKPG9sPgoJPGxpPlRIRSBVU0UgT1IgVEhFIElOQUJJTElUWSBUTyBVU0UgVEhFIFNFUlZJQ0U7PC9saT4KCTxsaT5USEUgQ09TVCBPRiBQUk9DVVJFTUVOVCBPRiBTVUJTVElUVVRFIEdPT0RTIEFORCBTRVJWSUNFUyBSRVNVTFRJTkcgRlJPTSBBTlkgR09PRFMsIERBVEEsIElORk9STUFUSU9OIE9SIFNFUlZJQ0VTIFBVUkNIQVNFRCBPUiBPQlRBSU5FRCBPUiBNRVNTQUdFUyBSRUNFSVZFRCBPUiBUUkFOU0FDVElPTlMgRU5URVJFRCBJTlRPIFRIUk9VR0ggT1IgRlJPTSBUSEUgU0VSVklDRTs8L2xpPgoJPGxpPlVOQVVUSE9SSVpFRCBBQ0NFU1MgVE8gT1IgQUxURVJBVElPTiBPRiBZT1VSIFRSQU5TTUlTU0lPTlMgT1IgREFUQTs8L2xpPgoJPGxpPlNUQVRFTUVOVFMgT1IgQ09ORFVDVCBPRiBBTlkgVEhJUkQgUEFSVFkgT04gVEhFIFNFUlZJQ0U7IE9SPC9saT4KCTxsaT5BTlkgT1RIRVIgTUFUVEVSIFJFTEFUSU5HIFRPIFRIRSBTRVJWSUNFLjwvbGk+Cjwvb2w+Cgo8cD48dT5CeSByZWdpc3RlcmluZyBhbmQgc3Vic2NyaWJpbmcgdG8gb3VyIGVtYWlsIGFuZCBTTVMgc2VydmljZSwgYnkgb3B0LWluLCBvbmxpbmUgcmVnaXN0cmF0aW9uIG9yIGJ5IGZpbGxpbmcgb3V0IGEgY2FyZCwgJnF1b3Q7eW91IGFncmVlIHRvIHRoZXNlIFRFUk1TIE9GIFNFUlZJQ0UmcXVvdDsgYW5kIHlvdSBhY2tub3dsZWRnZSBhbmQgdW5kZXJzdGFuZCB0aGUgYWJvdmUgdGVybXMgb2Ygc2VydmljZSBvdXRsaW5lZCBhbmQgZGV0YWlsZWQgZm9yIHlvdSB0b2RheS48L3U+PC9wPgoKPHA+Jm5ic3A7PC9wPgo8aGlnaGxpZ2h0IGNsYXNzPSJjb21wYW55TmFtZVVwZGF0ZSI+RGFsbGFzIExpdmluZzwvaGlnaGxpZ2h0PjxiciAvPgombmJzcDs="}
Write A Comment